论文部分内容阅读
据《华尔街日报》报道,美国食品药品监督管理局(FDA)没有批准Astra Zenca和Bristol Myers Squib的复方制剂dapagliflozin上市。根据报道,该医药公司发言人说,FDA要求更多的临床数据“以便对dapagliflozin的风险-获益状况进行更好评
According to The Wall Street Journal, the U.S. Food and Drug Administration (FDA) did not approve the listing of dapagliflozin, a combination of Astra Zenca and Bristol Myers Squib. According to reports, a spokesman for the pharmaceutical company said the FDA demanded more clinical data ”in order to better assess the risk-benefit status of dapagliflozin